News Roche finally drops curtain on AKT drug ipatasertib In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update
News Apogee buy delivers eczema trial win for AbbVie AbbVie's long-acting IL-13 inhibitor zumilokibart, part of its $10.9bn Apogee buy, has shown efficacy in atopic dermatitis and will move into phase 3.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
